Anti-BCL9L Antibody Picoband® (Dylight488 Conjugate)

B-cell CLL/lymphoma 9 like is a protein that in humans is encoded by the BCL9L gene. It is mapped to 11q23.3. Bcl-9 (B-cell lymphoma 9; also Protein legless homolog) is a transcriptional regulator that belongs to the Bcl-9 family of proteins. It is expressed in multiple tissues and serves to recruit Pygopus to the Wnt-pathway beta -catenin-TCF complex in the nucleus. Bcl-9 and Bcl-9-2 are considered evolutionary duplicates of Legless that perform the same task with different regulation. Human Bcl-9 is 1426 amino acids (aa) in length. It contains one phosphothreonine and three phosphoserine sites that have been identified so far, two poly-Pro regions (aa 514-517 and 970-973), and one poly-Ala segment (aa 900-903). There is one potential alternate start site at Met27, and a variant isoform exists that shows a four aa substitution for aa 13911426. Over aa 1009-1328, human Bcl-9 is 96% aa identical to mouse Bcl-9.

Expressed in breast, ductal and invasive ductal carcinomas of the breast, sporadic colorectal adenomas and carcinomas (at protein level). Expressed in fetal brain. Expressed in lung, amygdala, eye, prostate, pancreatic and prostate cancers, head and neck tumors and embryonal tumor.

Transcriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity. Plays a role in tumorigenesis. Enhances the neoplastic transforming activity of CTNNB1.

Store at -20℃ for one year from date of receipt. After reconstitution, at 4℃ for one month. It can also be aliquotted and stored frozen at -20℃ for six months. Avoid repeated freeze-thaw cycles.

Western blot, 0.1-0.5μg/ml, Human, Mouse, Rat<br> Immunohistochemistry (Paraffin-embedded Section), 0.5-1μg/ml, Human, By Heat<br> Immunocytochemistry/Immunofluorescence, 2μg/ml, Human<br> Flow Cytometry (Fixed), 1-3μg/1x10⁶ cells, Human<br> ELISA, 0.1-0.5μg/ml, -<br>